RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation
NASDAQ:RIGL • US7665597024
Current stock price
29.2 USD
-1.31 (-4.29%)
At close:
29.4 USD
+0.2 (+0.68%)
After Hours:
This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RIGL Profitability Analysis
1.1 Basic Checks
- In the past year RIGL was profitable.
- RIGL had a positive operating cash flow in the past year.
- In multiple years RIGL reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- RIGL's Return On Assets of 71.46% is amongst the best of the industry. RIGL outperforms 99.42% of its industry peers.
- With an excellent Return On Equity value of 93.75%, RIGL belongs to the best of the industry, outperforming 99.42% of the companies in the same industry.
- RIGL's Return On Invested Capital of 23.92% is amongst the best of the industry. RIGL outperforms 97.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROIC | 23.92% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of RIGL (124.72%) is better than 98.65% of its industry peers.
- RIGL has a Operating Margin of 42.63%. This is amongst the best in the industry. RIGL outperforms 98.45% of its industry peers.
- Looking at the Gross Margin, with a value of 93.33%, RIGL belongs to the top of the industry, outperforming 94.20% of the companies in the same industry.
- In the last couple of years the Gross Margin of RIGL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
2. RIGL Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
- RIGL has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, RIGL has less shares outstanding
- Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.57, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
- With a decent Altman-Z score value of 1.57, RIGL is doing good in the industry, outperforming 63.64% of the companies in the same industry.
- RIGL has a debt to FCF ratio of 0.69. This is a very positive value and a sign of high solvency as it would only need 0.69 years to pay back of all of its debts.
- RIGL has a better Debt to FCF ratio (0.69) than 94.97% of its industry peers.
- RIGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of RIGL (0.06) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 1.57 |
ROIC/WACC2.5
WACC9.56%
2.3 Liquidity
- RIGL has a Current Ratio of 2.42. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.42, RIGL is not doing good in the industry: 71.76% of the companies in the same industry are doing better.
- RIGL has a Quick Ratio of 2.30. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.30, RIGL is not doing good in the industry: 70.99% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 |
3. RIGL Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 593.62% over the past year.
- RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.15%.
- The Revenue has been growing by 22.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.44% on average over the next years.
- RIGL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.25% yearly.
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. RIGL Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 4.48, the valuation of RIGL can be described as very cheap.
- Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 98.65% of the companies are valued more expensively.
- RIGL is valuated cheaply when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 6.94, which indicates a rather cheap valuation of RIGL.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.45% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.54. RIGL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 6.94 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 98.65% of the companies are valued more expensively.
- RIGL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.13 | ||
| EV/EBITDA | 2.52 |
4.3 Compensation for Growth
- The decent profitability rating of RIGL may justify a higher PE ratio.
- RIGL's earnings are expected to decrease with -16.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
5. RIGL Dividend Analysis
5.1 Amount
- No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RIGL Fundamentals: All Metrics, Ratios and Statistics
29.2
-1.31 (-4.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-04 2026-05-04
Inst Owners90.16%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change6.76%
Market Cap539.62M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (78.84%)
Short Float %20.83%
Short Ratio10.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)8.94%
PT rev (3m)12.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)1.64%
EPS NY rev (3m)-4.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 6.94 | ||
| P/S | 1.83 | ||
| P/FCF | 7.13 | ||
| P/OCF | 7.13 | ||
| P/B | 1.38 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | 2.52 |
EPS(TTM)6.52
EY22.33%
EPS(NY)4.21
Fwd EY14.42%
FCF(TTM)4.09
FCFY14.02%
OCF(TTM)4.09
OCFY14.02%
SpS15.92
BVpS21.18
TBVpS19.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROCE | 30.28% | ||
| ROIC | 23.92% | ||
| ROICexc | 38.21% | ||
| ROICexgc | 42.24% | ||
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% | ||
| FCFM | 25.71% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | 19.09 | ||
| Cash Conversion | 59.16% | ||
| Profit Quality | 20.61% | ||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 1.57 |
F-Score6
WACC9.56%
ROIC/WACC2.5
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.48%
EBIT Next 3Y9.38%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
What is the profitability of RIGL stock?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the financial health for RIGL stock?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.
What is the earnings growth outlook for RIGEL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to decline by -35.44% in the next year.